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We have studied loss of heterozygosity at the BRCA1 and BRCA2 loci in 992 normal cell clones derived from topographically defined
areas of normal tissue in four samples from BRCA1/BRCA2 mutation carriers. The frequency of loss of heterozygosity in the clones
was low (1.01%), but it was found in all four samples, whether or not a tumour was present. Topographical mapping revealed that the
genetic changes were clustered in some breast samples. Our study confirms the previous finding that a field of genetic instability can
exist around a tumour, suggesting that sufficient tissue must be removed at surgery to avoid local recurrence. We also demonstrate
that such a field of genetic change can exist in morphologically normal tissue before a tumour develops and, for the first time, we
demonstrate that the field is of a size greater than one terminal duct-lobular unit. The genetic changes are not identical, however,
which suggests that genetic instability in these regions may play an early role in tumour development. We also confirm and extend
our original observation of loss of the wild-type BRCA1 allele in some clones, and loss of the mutant allele in others, demonstrating
that loss of either allele is a stochastic event.
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The term breast cancer encompasses a variety of tumour types
with differing clinical behaviour. In an attempt to understand the
pathways that give rise to these tumours, a number of studies
have examined the genetic changes in precursor lesions. Loss of
heterozygosity (LOH) studies have shown genetic alterations in
ductal carcinoma in situ (DCIS) (Stratton et al, 1995; Farabegoli
et al, 2002), lobular carcinoma in situ (Lakhani et al, 1995a; Vos
et al, 1997) atypical ductal hyperplasia (Lakhani et al, 1995b) and
nonatypical hyperplasia of the breast (Lakhani et al, 1996). Further
studies, using comparative genomic hybridisation have also
demonstrated a number of genetic changes in DCIS (Buerger
et al, 1999a,b), LCIS (Lu et al, 1998; Buerger et al, 2000),
hyperplasia of usual type (Jones et al, 2003), apocrine hyperplasia
(Jones et al, 2001) and columnar cell lesions (Simpson et al,
2005a). These studies support the idea that there may be several
pathways in the multistep model of carcinogenesis (Simpson et al,
2005b) and indicate that some benign lesions may be precursors to
invasive carcinoma.
It follows that the earliest genetic changes that fit into
this multistep model might be detected in cells that appear
morphologically normal. Such changes were demonstrated by
Deng et al (1996) who identified LOH in normal breast lobules
adjacent to, but not distant from tumours in sporadic
breast cancers. This study was carried out by examining LOH in
microdissected morphologically normal lobules. In order for such
changes to be detected using these techniques, the LOH must be
present in a high proportion of the cells in the microdissected
area. These results suggest, therefore, that the LOH probably
occurred in a cell that gave rise to the part of lobule that
was microdissected; however, it does not distinguish between
luminal and myoepithelial cell involvement. Meng et al (2004) also
demonstrated LOH in microdissected normal lobules adjacent to
tumours, and they reported for the first time LOH in the BRCA1,
BRCA2 and ATM genes in normal lobules adjacent to sporadic
tumours.
We have previously shown that genetic alterations are present in
normal breast cells both close to and distant from a tumour and in
tissue in which no tumour is present (Lakhani et al, 1999). These
results were achieved by cloning individual cells from pieces of
fresh human breast to give sufficient DNA to examine changes at
the single cell level, revealing alterations that might be missed
by looking at microdissected tissue. Furthermore, it allowed us
to look independently at the luminal epithelial and myoepithelial
cells. We established that LOH occurs in both luminal and
myoepithelial cells and, in one case, the same LOH was detected in
each cell type suggesting that the two cell types came from a
common precursor.
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sMicrodissection has been used to demonstrate LOH in normal
lobules in familial breast cancers (Cavalli et al, 2004). Cavalli et al
detected LOH in normal tissues adjacent to and, in one case, at
a distance up to 8.7mm from the tumour. In addition LOH was
detected in areas of sclerosing adenosis both in the tumour-
containing breast and in the contralateral prophylactic mastect-
omy. In all cases of LOH at the BRCA loci the wild-type allele was
lost.
Larson et al (2005) compared the levels of LOH in normal
lobules from BRCA1 carriers, patients with sporadic cancer and
reduction mammoplasty specimens. They found a three-fold
increase in the level of allelic imbalance in the normal tissues
from patients with sporadic cancers or those with a BRCA1
mutation compared to reduction mammoplasty specimens; how-
ever, the distance of the microdissected terminal duct-lobular units
(TDLUs) from the tumour was not recorded. Ellsworth et al (2004)
examined the distribution of LOH in microdissected samples from
different quadrants of mastectomy specimens in sporadic breast
cancer. They demonstrated increased levels of LOH in the outer
quadrants of the breast, with the highest level in the lower outer
quadrant in which the majority of tumours were found.
In the current study we have applied our cell cloning technique
to mastectomy and prophylactic mastectomy samples from
patients with a mutation in either BRCA1 or BRCA2. We have
analysed the frequency of LOH in these samples, the losses of
mutant and wild-type alleles, and by taking tissue from defined
areas of the breast we have mapped the distribution of the losses.
MATERIALS AND METHODS
Tissue samples
The use of normal breast tissue was approved by the Ethics
Committee of the Royal Marsden Hospital and the Institute of
Cancer Research. Normal breast tissue samples were obtained with
informed consent from three patients undergoing mastectomy
and/or prophylactic mastectomy. The first case consisted of a
tumour-bearing (mastectomy) specimen. In the second case, the
whole mastectomy specimen was required for pathological
diagnosis; however, samples from the contralateral prophylactic
mastectomy were available for this study. In the third case, tissue
was available from both the tumour-carrying breast and the
contralateral unaffected breast. In total, therefore, we used a total
of four separate breast specimens: two mastectomies and two
prophylactic mastectomies. Fresh unfixed breast specimens were
sliced and examined by a pathologist and pieces of normal tissues
from multiple sites throughout the breast were selected and their
positions recorded. The rest of the specimen was examined and
processed routinely. Paraffin-embedded samples of tumour-free
lymph node removed at surgery were used as normal controls.
Paraffin embedded tumour samples were used to investigate LOH
in the tumour and, by inference, establish which were the mutant
and wild-type alleles, the loss in the tumour being assumed to be
wild-type.
Normal cell cloning
Tissue samples were cut into small fragments using scissors and/or
scalpels and then incubated with stirring at 371C overnight in a
solution of 0.5mgml
 1 collagenase (Type 1, Sigma, Poole, Dorset,
UK) in Leibovitz L-15 medium plus 5% foetal calf serum. The
tissue fragments were collected by centrifugation and then passed
sequentially through a 70mm and a 40-mm cell strainer (Falcon)
to collect the epithelial fragments and remove the single cells
consisting predominantly of fibroblasts, endothelial and blood
cells. The epithelial fragments were plated in RPMI medium plus
10% FCS, 5mgml
 1 hydrocortisone, 5mgml
 1 insulin and
100ngml
 1 cholera toxin (all additives from Sigma). The epithelial
cells were allowed to mobilise from the fragments for approxi-
mately 5 days, and were then trypsinised to form a single-cell
suspension. The cells were plated in 15cm Petri dishes (1000 cells
per dish), which had been preseeded with 10
6 lethally irradiated
(40Gy) mouse 3T6 fibroblasts. The clones were grown in Ham’s
F12 medium plus 10% FCS, 1mgml
 1 hydrocortisone, 5mgml
 1
insulin, 10ngml
 1 human recombinant EGF and 100ngml
 1
cholera toxin (all additives from Sigma). This medium results in
the clonal growth of both luminal and myoepithelial cells, but does
not allow the growth of primary tumour cells under clonal
conditions (Wolman et al, 1985; O’Hare, 1990). After 10–14 days
the clones of epithelial cells were fixed for 3min in ice-cold
methanol, rinsed in several changes of PBS and stored in PBS for
immunofluorescent labelling.
Immunofluorescent labelling
The clones were labelled by triple immunofluorescence for the
expression of cytokeratins 18 and 19 (predominantly luminal cells
in vivo) and cytokeratin 14 (predominantly myoepithelial cells in
vivo). Two antibodies were used to identify luminal cell clones
because, in our hands, up to 30% of luminal clones will have only
weak or absent expression of one or other of the cytokeratins in
culture (unpublished observation). The primary antibodies were
applied as a cocktail as follows: LL002 (mouse monoclonal IgG3
anti-CK14, Novocastra) 1:200, DC10 (mouse monoclonal IgG1
anti-CK18, Novocastra) 1:200, LP2K (mouse monoclonal IgG2b
anti-CK19, a kind gift of Professor EB Lane, Dundee, UK) 1:5.
These antibodies were detected with a cocktail of goat-anti-mouse
subclass-specific secondary antibodies (Southern Biotechnology)
as follows: biotinylated anti-IgG3, FITC anti-IgG1, Texas Red anti-
IgG2b, followed by a tertiary layer of streptavidin AMCA, resulting
in CK18 seen as green, CK19 blue and CK14 red. The clones were
examined using a Zeiss Axiovert fluorescence microscope and
individually scored for the expression of each antigen to identify
the cell type of origin.
LOH analysis
Following identification of cell type by immunofluorescence, each
clone was scraped from the culture plate. DNA was extracted from
the clones or the paraffin sections of tumour or normal lymph
node control using proteinase K digestion as previously described
(Lakhani et al, 1996). Dinucleotide repeat regions of polymorphic
microsatellite markers ranging in size from 119 to 185 base pairs in
the regions of the BRCA1 or BRCA2 genes were examined. These
markers were: D17s250, D17s800, D17s806 and D17s1814 in the
region of BRCA1 (17q21), D17s855, D17s1323 and D17s1322
intragenic of BRCA1, and D13s267, D13s260 and D13s1293 in the
region of BRCA2 (13q13). Loss of heterozygosity was investigated
at these markers by amplification using fluorescently tagged
primers and the polymerase chain reaction (PCR). The products
were run on an ABI prism 377 and the data were processed using
GeneScan Analysis software (version 3.1) followed by Genotyper
software (version 2.5).
RESULTS
LOH frequency and distribution
Clones from four breast samples (one from a BRCA2 mutation
carrier, three from BRCA1 mutation carriers) were analysed for
the presence of LOH. Of these, two samples had tumour present
and two were prophylactic mastectomies. For the prophylactic
mastectomies, in each case the contralateral breast contained
tumour. A summary of the results of these analyses are presented
in Table 1 including the number of clones harvested from
LOH in normal cells in BRCA1/2 carriers
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seach breast sample, and the number of microsatellite markers
examined per sample. In the BRCA2 sample, all three
microsatellites studied were informative, but no further DNA
was available to study other markers. In the BRCA1 samples,
seven microsatellite markers were studied (six BRCA1 and
one BRCA2), but only six were informative in each case:
D17s800 was not informative (homozygous) in sample 2, and
D17s1322 was not informative in samples 3 and 4. In total, 5355
microsatellites were examined across the four samples. In these
samples the wild-type allele was considered to be the allele lost in
the tumour samples.
The rate of LOH in each case was low (0.739–1.579% of
clones) but it was detected in all samples, both in the presence
and absence of tumour. In sample 1, two luminal clones had
LOH at D13s1293, both losses of the peak from the wild-type
allele (hereafter referred to as loss of wild-type). In sample 2, one
luminal and one myoepithelial clone showed LOH at D17s806 (loss
of wild-type). Sample 3 had a total of three LOH all in
luminal epithelial cells. Two of the clones were adjacent to the
tumour, one showing LOH in D17s1814 (loss of wild-type) and
the other in D17s1323 (loss of mutant). The third clone with
LOH at D17s1814 (loss of wild-type) appears to be distant from
the tumour and the other clones showing LOH (Figure 1), but it
is in fact within 2cm of the other alterations since the breast
tissue was cut into very thin slices. Sample 4 (the contralateral
breast to sample 3) also had three clones within a small area
of breast exhibiting LOH (two in the same slice, one within 1cm).
The cell type and alterations were, however, all different:
one luminal clone had LOH at D17s1814 (loss of wild-type), one
myoepithelial clone had LOH at D17s1323 (loss of mutant) and
another had a loss at D13s267 (a BRCA2 microsatellite). In
each case, no clone had LOH at more than one microsatellite.
Examples of LOH found in clones from samples 3 and 4 are shown
in Figure 2.
Wild-type and mutant alleles
A summary of the losses from the wild-type and mutant alleles is
presented in Table 1. A total of nine LOH were detected in the
regions of BRCA2 in sample 1 and BRCA1 in samples 2–4. Of
the nine LOH, seven were wild-type and two mutant losses. Two of
the wild-type losses were in clones from the BRCA2 case; however,
D13s267 which is closer to BRCA2 showed no LOH, and therefore
the gene was not likely to be inactivated. In the BRCA1 cases, both
of the mutant losses were intragenic, and the wild-type losses were
in the markers closest to the BRCA1 gene. In the latter cases, it was
not clear whether the area of loss extended into the gene, and since
there was not enough DNA available to sequence the gene we
could not establish whether the wild-type allele was inactivated.
The proportions of losses of microsatellites on the wild-type and
mutant alleles were tested to see if they were equal using a w
2 test,
and the difference did not reach significance (P¼0.22).
DISCUSSION
In this study we have investigated the frequency and distribution
of LOH in normal breast tissue from patients carrying a mutation
in the BRCA1 or BRCA2 genes, using a single cell cloning
technique.
It might be argued that the cloning process may produce LOH,
particularly in cells with BRCA1/2 mutations. If the alterations










1 Mastectomy BRCA2 199 3 2 wt 1.005
2 Prophylactic BRCA1 197 6 2 wt 1.015
3 Mastectomy BRCA1 406 6 2 wt, 1 mut 0.739




Wt¼loss from wild-type allele, mut¼loss from mutant allele.
Figure 1 Distribution of LOH detected in areas of histologically normal
tissue of a mastectomy specimen (sample 3). Areas of tissue from which
cells were cloned are shown in white, tumour is shown in black (T).






Sample 3 luminal clone








Figure 2 Loss of heterozygosity in normal cell clones demonstrated
by amplification of microsatellites D17s1323 (A) and D13s267 (B). The
normal tissue control for each sample shows two allele peaks. The ‘normal’
clones from samples 3 and 4 each demonstrate loss of one allele (arrow).
LOH in normal cells in BRCA1/2 carriers
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soccurred during the growth of the clone, however, only a
proportion of the cells would carry the LOH, and this would be
reflected in the levels of each peak on the Genescan analysis. In this
study, each clone showed complete loss of one peak, indicating
that the LOH was present in all the cells, and therefore must have
occurred before the growth of the clone.
In our previous study only one LOH was found in three
reduction mammoplasty samples (Lakhani et al, 1999). In contrast,
both of the prophylactic mastectomies (from BRCA1/2 mutation
carriers) in the current study contained clones with LOH. This
result is consistent with the previously reported three-fold increase
in LOH in normal TDLUs from BRCA1 carriers compared to
reduction mammoplasties (Larson et al, 2005). The level of LOH in
the mastectomies (with tumour) from the two studies, however,
appears to show a large difference: 0.83% of clones in the BRCA
cases and 7.6% in the non-BRCA cases. The majority of LOH found
in the non-BRCA cases, however, were in a single sample in which
all clones showed LOH, suggesting that the loss occurred very early
in the development of the breast. Without this case, the level of
LOH in the non-BRCA cases drops to 0.68%. This result illustrates
the difficulty of examining changes that could potentially occur
at any time during the development of the breast and thus affect
anything from a single cell to the whole organ.
These studies are particularly labour intensive, making it
impractical to examine many samples in order to produce
statistically significant results. Nevertheless, some interesting
observations of distribution and allele loss have still arisen from
this study. We have shown that LOH is found close to tumours, and
is sometimes found in other areas of the breast. In particular, we
have shown that genetic alterations at the single-cell level may be
clustered, and extend to an area that consists of more than one
TDLU. Such clustering suggests that a change may have occurred in
a precursor cell, which gave rise to that area of the breast. This result
complements the findings of Tot (2005), who observed that multiple
foci of DCIS are sometimes found within a single lobe of the breast,
and suggests that an early genetic event may give rise to a ‘sick lobe’.
In our samples, it is unlikely that an early event in BRCA1 is
responsible for the apparent field of genetic instability since the
LOH vary in the different clones in a single area. Indeed, it is not
clear whether the losses from the wild-type allele in the clones from
the BRCA1 cases extend into the gene, and thus we cannot comment
on whether BRCA1 function is lost. Although this clearly has
implications for disease pathogenesis since losses that do not extend
into the BRCA1 gene should not contribute to breast tumouro-
genesis, nevertheless, the clustering of the losses still suggests the
presence of an underlying instability in an area of the breast. In
order to further elucidate the mechanism of genetic change in these
areas, it would be interesting to analyse the whole genome using
SNP arrays (Zhou et al, 2005), and we anticipate that this approach
will become possible as DNA amplification methods improve.
Our finding of clusters of LOH has clinical implications. Firstly,
our results may help to account for some local tumour recurrences
following apparent surgical clearance. The ‘recurrence’ may
actually be a new tumour formed in the area of underlying
genetic changes close to the original tumour. If this is the case, it
implies that the rate of ‘recurrence’ may be reduced by removing
more tissue at surgery. Secondly, one patient had two clusters of
LOH, one close to the tumour and the other in the contralateral
breast. It is impossible to know whether the area of LOH in the
non-diseased breast might have gone on to form a clonal
proliferation/tumour.
Our studies have demonstrated a second novel observation:
loss of either the mutant or wild-type allele at microsatellite
markers in the BRCA1 region (Lakhani et al, 1999). Loss of
the wild-type BRCA1 or BRCA2 allele has been shown in breast
tumours arising in patients carrying a germline mutation in one of
these genes (Collins et al, 1995; Cornelis et al, 1995; Merajver et al,
1995; Osorio et al, 2002) and in some sporadic breast tumours
(Hanby et al, 2000; Katsama et al, 2000; Johnson et al, 2002).
The loss of the wild-type allele is presumed to be one of the
first genetic events leading to tumour formation in familial
breast cancer cases (Cornelis et al, 1995). It can be argued that
the mutant allele is equally likely to be lost in normal cells, but
since this will result in the maintenance of haploid sufficiency of
the BRCA genes, the cells should not be expected to go on to form
a tumour. Our results show that microsatellite markers on either
the wild type or the mutant allele may be lost; however, Cavalli
et al demonstrated only loss of the wild-type allele in their normal
breast samples (Cavalli et al, 2004). The difference in the results
suggests that although LOH at either allele may be a stochastic
event, it appears that only those cells that have lost the wild-type
allele go on to form clonal expansions that will populate the
lobules. It is possible that the loss of functional BRCA1 may lead to
a series of genetic alterations that give the cells a growth advantage
so that they are more likely to form areas carrying the LOH.
Interestingly, in our previously reported sample (Lakhani et al,
1999), one of the clones with a confirmed intragenic wild-type loss
also showed losses at 11p and 13q suggesting that this process may
have been underway.
We have shown in this study that areas of genetic alterations are
present in normal breast tissues of BRCA1/2 carriers, and that
LOH at BRCA1/2 is possibly an early, but not necessarily the
earliest event. Further studies using alternative techniques such as
SNP arrays will be required to fully understand the sequence of
events that leads to tumour formation in these tissues.
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